14 Oct 2025 | 5 Mins Read
J&J spins off orthopedics, raises year forecast
Flipitmoney
Johnson & Johnson plans to separate its orthopedics business, DePuy Synthes, into a standalone company within 18-24 months. The $9.2 billion unit generated 10% of total revenue in 2023. The company will focus on high-growth areas like oncology and neuroscience, citing that the next phase of orthopedic innovation was "beyond our scope." Revenue forecast is raised to $93.5 billion-$93.9 billion.